Pediatric Praziquantel Consortium awarded US$1.86 million GHIT grant
The Pediatric Praziquantel Consortium, launched in 2012 as an international non-profit public-private partnership, has announced that it has been awarded a prestigious research grant from the Japanese Global Health Innovative Technology (GHIT) Fund.
The grant supports the Consortium’s clinical development program of a newly developed praziquantel pediatric formulation targeted for use in very young children, including infants and toddlers, infected with schistosomiasis.
"GHIT grants are awarded on the basis of a highly competitive, double peer review process, which underlines the importance of a newly developed praziquantel pediatric medication for millions of infected children in the developing world" said Annalisa Jenkins, Chair of the Consortium Board and Head of Global R&D at Merck Serono. "We very much look forward to working with the GHIT Fund and are grateful for its support in addressing the global health burden that schistosomiasis represents.”, she added. BT Slingsby, CEO of the GHIT Fund, said: “We welcome collaboration with the Pediatric Praziquantel Consortium. This project will enable Japanese formulation technology and innovation to play a more direct role in the fight against the second-most severe tropical disease in Africa.”
The standard recommended praziquantel treatment is available in tablets, suitable for adults and children from the age of six. Proper treatment of younger children with schistosomiasis is hampered due to missing clinical data and the fact that they cannot swallow these tablets because of their size and bitter taste. Astellas Pharma has played a pivotal role in the development of new oral dispersible praziquantel candidates specifically for very young children. As Kazuhiro Sako, fellow Consortium Board member and Vice President Pharmaceutical Research and Technology Labs at Astellas Pharma, explained: “The newly developed tablet has been reduced to a quarter of the size of the current commercial praziquantel tablet to swallow easily. We designed it to be oral dispersible so that it can be taken with or without water, allowing treatment, in principle, of very young children, including infants from 3 months onwards.” He added: “A major challenge, which required a great deal of effort, was to reduce the bitter taste but at the same time keep the formulation straightforward and robust, to allow future local manufacturing and storage in endemic countries.”
Whether taste masking has been successful remains to be determined. A taste study in African children is planned during the first half of 2015, in which the newly developed praziquantel candidates are compared to the commercial praziquantel. This study is preceded by two phase I clinical trials in healthy adult volunteers in the second half of 2014. In addition to funding three clinical studies, the research grant is intended to cover the costs of a high-level expert meeting in which the future regulatory and access strategy will be discussed and the costs of communication activities. The funding by GHIT will help the Consortium to take one of the praziquantel candidates to the phase II clinical trial stage.